[Drug therapy interventions for acute SARS-CoV-2 infection: who, when, and what?]
- PMID: 36195089
- DOI: 10.1055/a-1817-8872
[Drug therapy interventions for acute SARS-CoV-2 infection: who, when, and what?]
Abstract
There is a variety of drug therapy options for treatment of acute SARS-CoV-2 infections. The updated S3 guideline "Recommendations for inpatient therapy of patients with COVID-19" provides clear recommendations in this regard. Which therapy is best suited for which patient and in which phase of the disease must be decided individually based on risk factors, comorbidities and contraindications. This article provides an overview.
Thieme. All rights reserved.
Conflict of interest statement
Barbara Sensen gibt an, dass kein Interessenkonflikt besteht.Dominic Wichmann: Beratertätigkeit: Eumedica, EUSA-Pharm, Gilead, Kite, Lilly, MSD, Novartis, Pfizer, Shionogi. Vortragshonorare: Advanz, Gilead, 3 M, MSD, Pfizer, Shionogi.Stefan Kluge: Forschungsunterstützung: Cytosorbents, Daiichi Sankyo. Vortragstätigkeit: Biotest, Daiichi Sankyo, Fresenius Medical Care, Gilead, Mitsubishi Tanabe Pharma, MSD, Pfizer, Zoll. Beratertätigkeit: Fresenius, Gilead, MSD, Pfizer.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Miscellaneous